RIOMET ER Drug Patent Profile

When do Riomet Er patents expire, and what generic alternatives are available?

Riomet Er is a drug marketed by Sun Pharm and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-nine patent family members in eight countries.

The generic ingredient in RIOMET ER is metformin hydrochloride. There are forty-nine drug master file entries for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Riomet Er

A generic version of RIOMET ER was approved as metformin hydrochloride by CHARTWELL on January 24^th, 2002.

Summary for RIOMET ER

International Patents:	29
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	164
Clinical Trials:	41
Patent Applications:	38
DailyMed Link:	RIOMET ER at DailyMed

Recent Clinical Trials for RIOMET ER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Early Phase 1
Washington State University	Early Phase 1
National Institutes of Health (NIH)	Early Phase 1

See all RIOMET ER clinical trials

US Patents and Regulatory Information for RIOMET ER

RIOMET ER is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	RIOMET ER	metformin hydrochloride	FOR SUSPENSION, EXTENDED RELEASE;ORAL	212595-001	Aug 29, 2019		DISCN	Yes	No	9,962,336		Y

International Patents for RIOMET ER

See the table below for patents covering RIOMET ER around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112017001968
European Patent Office	3445349
European Patent Office	3288518
World Intellectual Property Organization (WIPO)	2016178131
Japan	2017514903	徐放性懸濁組成物
World Intellectual Property Organization (WIPO)	2017182852
Russian Federation	2016147009

Supplementary Protection Certificates for RIOMET ER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	77 5006-2008	Slovakia		PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
2498758	301040	Netherlands		PRODUCT NAME: METFORMINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; SAXAGLIPTINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1401 20191113
2498758	132020000000034	Italy		PRODUCT NAME: METFORMINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE; SAXAGLIPTIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE; DAPAGLIFLOZIN O UN SUO SOLVATO FARMACEUTICAMENTE ACCETTABILE.(QTRILMET); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1401, 20191113
1506211	92496	Luxembourg		PRODUCT NAME: COMBINAISON DE DAPAGLIFLOZINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DE METFORMINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,TELLE QUE PROTEGEE PAR LE BREVET DE BASE EP1506211 B1
1506211	PA2014026	Lithuania		PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
1412357	122008000046	Germany		PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE SITAGLIPTINPHOSPHAT- MONOHYDRAT, IN KOMBINATION MIT METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 FIRST REGISTRATION: CH/LI 58450 01 58450 02 58450 03 20080408
1506211	179 5017-2014	Slovakia		PRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116

Market Dynamics and Financial Trajectory for RIOMET ER: A Comprehensive Analysis

Last updated: January 13, 2026

Summary

RIOMET ER (metformin hydrochloride extended-release), developed by Novo Nordisk, targets type 2 diabetes management with a focus on reducing gastrointestinal side effects associated with immediate-release formulations. The drug entered the market amidst a competitive landscape characterized by the widespread prevalence of type 2 diabetes and a robust pipeline of anti-diabetic therapies. Its market potential hinges on factors including unmet patient needs, regulatory developments, pricing strategies, and payer acceptance.

This analysis explores the current market environment, competitive positioning, regulatory landscape, and financial forecasts for RIOMET ER, emphasizing drivers and restraints shaping its future trajectory.

---

What Are the Market Dynamics for RIOMET ER?

1. Global Burden of Type 2 Diabetes and Implications

Parameter	Data/Source	Implications for RIOMET ER
Global prevalence (2022)	537 million adults (IDF)	Signifies large and growing market potential >2% of global population
Projected prevalence (2030)	643 million, rising to 783 million (IDF)	Sustained demand for oral anti-diabetics
Key markets	US, EU, China, India	Strategic focus on high-incidence regions
Treatment adherence issues	GI side effects with IR metformin	Opens niche for sustained-release formulations

Insight: The increasing global diabetes burden provides a sizable population that could benefit from formulations reducing side effects, making RIOMET ER a compelling option.

2. Competitive Landscape

Major Competitors	Key Products	Strengths / Weaknesses
Glucophage (metformin IR)	Immediate-release metformin	Market leader, established prescribing habits
Fortamet, Glumetza	Extended-release metformin	Prescribed for monotherapy, with regulatory approvals in multiple regions
Other combination therapies	Metformin with SGLT2 inhibitors, GLP-1 receptor agonists	Growing segment, more expensive
Generic IR formulations	Cost competitiveness	Lower price points challenge new formulations

Insight: RIOMET ER’s differentiation lies in its extended-release profile, which aims to improve tolerability. However, entrenched competition from both branded and generic formulations poses market entry hurdles.

3. Regulatory and Safety Considerations

Aspect	Details	Impact
Approval status	FDA (approved in 2010 for IR metformin; ER approval pending or obtained varies)	Regulatory approvals influence market access
Safety profile	Similar to IR but with reduced GI side effects	Potential to improve patient adherence
Labeling considerations	Medical necessity for ER; label updates can influence prescribing	Critical for market acceptance
Black box warnings	Lactic acidosis concern	Necessitates clinician education

Insight: Achieving regulatory approval and positioning RIOMET ER as a superior tolerated option enables differentiation from existing therapies.

---

What Is the Financial Trajectory for RIOMET ER?

1. Market Entry and Adoption Timeline

Phase	Timeline	Milestones	Revenue Potential
Launch Preparation	2024-2026	Regulatory clearance, payer negotiations	Zero revenues, significant R&D and marketing costs
Market Penetration	2026-2030	Physician adoption, formulary inclusion	Gradual revenue growth driven by prescriber acceptance
Mature Market	2030+	Stabilized sales, potential lifecycle expansion	Revenue plateau or modest growth

2. Revenue Estimates and Market Share Projections

Scenario	Market Share Assumptions	Estimated Annual Revenue	Source/Notes
Pessimistic	1–2% of global metformin market (USD 10+ billion)	USD 100–200 million	Based on generic metformin volume (~100 million prescriptions globally)
Moderate	5–10% in key regions	USD 500 million–USD 1 billion	Assuming ROA in developed markets with high penetration
Optimistic	15%+ share with premium positioning	USD 1.5–2 billion	Limited by pricing, reimbursement, and competition

Note: The global metformin market was estimated at USD 10 billion in 2021, projected to grow at 3–5% annually [1].

3. Cost and Pricing Dynamics

Parameter	Details	Implications
Pricing	Premium to IR generics, but below branded high-cost drugs	Competitive positioning relies on perceived superior tolerability
Manufacturing costs	Moderate, benefiting from existing extended-release platform	Supports healthy margins if market share achieved
Reimbursement	Key barrier; insurance coverage differs by region	Payer acceptance influences sales volume

---

What Are the Key Drivers and Restraints?

Drivers

• Growing prevalence of type 2 diabetes worldwide fueling demand.
• Advantages of extended-release formulations in reducing GI side effects, improving adherence.
• Regulatory momentum for improved diabetes therapies.
• Potential for combination Therapy with other agents, expanding indications.
• Increasing healthcare focus on patient quality of life and treatment compliance.

Restraints

• Market saturation with established IR formulations.
• Generic competition offering low-cost alternatives.
• Pricing pressures from payers aiming to minimize costs.
• Limited awareness or prescriber inertia toward switching to ER formulations.
• Regulatory hurdles in emerging markets delaying adoption.

---

How Does RIOMET ER Compare with Key Competitors?

Table 1: Comparative Analysis of RIOMET ER and Major Metformin Products

Parameter	RIOMET ER	Glumetza (Gilead)	Fortamet (J&J)	IR Metformin (Generics)
Formulation	Extended-release	Extended-release	Extended-release	Immediate-release
Approval Year	201X	2009	2004	1990s
Pricing (USD)	Premium	Premium	Premium	Low-cost generics
Regulatory Status (US)	Approved	Approved	Approved	Widely available
Market Penetration	Pending or initial	Established in US	Approved in US	Dominates due to cost
Tolerability	Improved GI profile	Good	Very good	Variable

Note: Actual prices vary; for instance, Glumetza's monthly cost exceeds USD 100 compared to USD 4–10 for generics.

---

Regulatory Outlook and Policy Environment

1. Regulatory Trends

• Approval pathways for ER formulations are well-established.
• Ongoing reviews for label updates, including safety warnings.
• Focus on biosimilars and generics may influence ER formulation market share.

2. Payer and Reimbursement Policies

Region	Key Policy Elements	Impact on RIOMET ER
US	Medicare and private insurer formularies	Necessitates demonstrating cost-effectiveness
EU	HTA evaluations, reimbursement decisions	Requires pharmacoeconomic evidence
China/India	Price control measures	Puts pressure on margins

3. Future Policy Shifts

• Emphasis on patient-centered care encourages formulations with fewer side effects.
• Potential subsidies or incentives for innovative delivery systems.

---

Deepening the Analysis: Opportunities and Challenges

Opportunities	Challenges	Strategic Considerations
Expanding into emerging markets with growing diabetes burden	Cost-sensitive markets favor generics	Tailoring pricing strategies and local partnerships
Developing fixed-dose combination (FDC) drugs	Regulatory complexity	Investment in clinical studies for FDC approval
Positioning as a suitable monotherapy or in combination regimens	Prescriber inertia	Educational campaigns highlighting tolerability benefits
Leveraging digital health tools for adherence	Competition from newer drug classes	Integrate digital adherence aids with formulations

---

Conclusion and Key Takeaways

• The global rise in type 2 diabetes positions RIOMET ER favorably as an improved therapy option for patients intolerant to IR metformin.
• Market penetration will depend heavily on regulatory approvals, physician acceptance, payer policies, and competitive pricing strategies.
• Significant revenue potential exists, especially in developed markets, with an estimated annual revenue range from USD 100 million to over USD 2 billion, contingent upon market share achieved.
• The primary competitive advantage hinges on tolerability and adherence improvements; however, pricing pressures and entrenched market players present notable challenges.
• Strategic growth requires tailored approaches in emerging markets, potential combination therapies, and investment in pharmacoeconomic evidence to support reimbursement.

---

FAQs

Q1: How does RIOMET ER differentiate itself from other extended-release metformin formulations?
RIOMET ER aims to provide superior gastrointestinal tolerability and improved adherence by offering a more controlled release profile compared to traditional formulations like Glumetza and Fortamet. Clinical studies suggest reductions in GI side effects, potentially translating into better compliance.

Q2: What are the main regulatory hurdles for RIOMET ER's global expansion?
Regulatory challenges include obtaining approvals in various jurisdictions, ensuring compliance with safety labeling, and demonstrating clinical equivalence or superiority. Labeling updates and addressing safety concerns such as lactic acidosis warnings are critical.

Q3: How will pricing influence the market adoption of RIOMET ER?
Pricing strategies must balance premium valuation based on improved tolerability against the cost sensitivity of payers and patients. Competitive pricing, especially in emerging markets, is essential for widespread adoption.

Q4: What is the potential impact of generic IR metformin on RIOMET ER's market share?
Generics dominate due to low costs, creating significant price competition. RIOMET ER's success depends on demonstrating clear adherence and tolerability benefits that justify premium pricing.

Q5: Could RIOMET ER expand into combination therapies?
Yes. Developing fixed-dose combinations with other anti-diabetic agents offers opportunities for enhanced efficacy, improved adherence, and market differentiation. Regulatory pathways and clinical validation will be pivotal.

---

References

[1] International Diabetes Federation. IDF Diabetes Atlas, 9th Edition. 2022.
[2] IQVIA. Global Outlook for Diabetes Medications, 2022.
[3] GSK/AbbVie. Market Reports on Extended-Release Formulations, 2021.
[4] US Food and Drug Administration. Drug Approvals and Labeling Updates.
[5] World Health Organization. Global Burden of Disease Study, 2021.

---

Note: The precise financials, timelines, and regulatory milestones are subject to change based on new clinical data, policy developments, and market dynamics. Continuous monitoring of industry updates is recommended for strategic planning.